Identification of serum microRNAs as diagnostic and prognostic biomarkers for acute pancreatitis

Pi, Li; Xia, Liang; Zhang, Weilong; Ke, Huajing; Su, Tao; Deng, Libing; Chen, Youxiang; Lv, Nonghua

doi:10.1016/j.pan.2014.03.019

Cited by 39 publications

(50 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, circulating levels of miR-10a are reduced in patients suffering from acute pancreatitis, 43 and exposure to microbiota can downregulate miR-10a in dendritic cells in an NF-kBdependent manner. 44 Importantly, miR-10a levels are also decreased in atherosclerotic plaque.…”

Section: Discussionmentioning

confidence: 99%

Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs

Njock

Cheng

Dang

et al. 2015

Blood

227

188

View full text Add to dashboard Cite

Key Points• Quiescent endothelial cells secrete extracellular vesicles that can be taken up by monocytes to suppress their activation.• MiR-10a is transferred to monocytic cells and inhibits the activation of the proinflammatory nuclear factor kB pathway.The blood contains high concentrations of circulating extracellular vesicles (EVs), and their levels and contents are altered in several disease states, including cardiovascular disease. However, the function of circulating EVs, especially the microRNAs (miRNAs) that they contain, are poorly understood. We sought to determine the effect of secreted vesicles produced by quiescent endothelial cells (ECs) on monocyte inflammatory responses and to assess whether transfer of microRNAs occurs between these cells. We observed that monocytic cells cocultured (but not in contact) with ECs were refractory to inflammatory activation. Further characterization revealed that endothelium-derived EVs (EC-EVs) suppressed monocyte activation by enhancing immunomodulatory responses and diminishing proinflammatory responses. EVs isolated from mouse plasma also suppressed monocyte activation. Importantly, injection of EC-EVs in vivo repressed monocyte/macrophage activation, confirming our in vitro findings. We found that several antiinflammatory microRNAs were elevated in EC-EV-treated monocytes. In particular, miR-10a was transferred to monocytic cells from EC-EVs and could repress inflammatory signaling through the targeting of several components of the NF-kB pathway, including IRAK4. Our findings reveal that ECs secrete EVs that can modulate monocyte activation and suggest that altered EV secretion and/or microRNA content may affect vascular inflammation in the setting of cardiovascular disease. (Blood. 2015;125(20):3202-3212)

show abstract

Section: Discussionmentioning

confidence: 99%

Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs

Njock

Cheng

Dang

et al. 2015

Blood

227

188

View full text Add to dashboard Cite

show abstract

“…Specific criteria for miRNA selection such as abundance in patient serum, organ specificity and significance for organ injury were established. Additionally, we included in our analysis those miRNAs which were prognostic biomarkers for acute pancreatitis, according to a recent paper by Liu et al [21].…”

Section: Methodsmentioning

confidence: 99%

“…To improve patient diagnostics and predict outcome in AP patients, new strategies based on miRNAs have been proposed recently [15,20,21]. However, results of some clinical studies are not concordant with animal (rat) models, where different microRNAs have been selected (e.g., miR-15b, miR-16, miR-216a) [22,23].…”

Section: Introductionmentioning

confidence: 99%

Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis

et al. 2015

View full text Add to dashboard Cite

“…Compared with CEA, miR-7 has a higher receiver operating characteristic curve, sensitivity and specificity (0.897, 82% and 89%, respectively). Similarly, by analyzing the serum from 12 acute pancreatitis patients and three healthy controls, Liu et al [46] identified miR7 as one of the three diagnostic and prognostic biomarkers. Although several systematic reviews [44,[47][48][49] have investigated biomarkers for GC, none has shown that miR-7 could be a biomarker of GC.…”

Section: Circulatory Biomarkermentioning

confidence: 99%

Role of microRNA-7 in digestive system malignancy

Chen¹

2016

WJGO

View full text Add to dashboard Cite

There are several malignancies of the digestive system (including gastric, pancreatic and colorectal cancers, and hepatocellular carcinoma), which are the most common types of cancer and a major cause of death worldwide. MicroRNA (miR)-7 is abundant in the pancreas, playing an important role in pancreatic development and endocrine function. Expression of miR-7 is downregulated in digestive system malignancies compared with normal tissue. Although there are contrasting results for miR-7 expression, almost all research reveals that miR-7 is a tumor suppressor, by targeting various genes in specific pathways. Moreover, miR-7 can target different genes simultaneously in different malignancies of the digestive system. By acting on many cytokines, miR-7 is also involved in many gastrointestinal inflammatory diseases as a significant carcinogenic factor. Consequently, miR-7 might be a biomarker or therapeutic target gene in digestive system malignancies.

show abstract

Identification of serum microRNAs as diagnostic and prognostic biomarkers for acute pancreatitis

Cited by 39 publications

References 37 publications

Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs

Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs

Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis

Role of microRNA-7 in digestive system malignancy

Contact Info

Product

Resources

About